Advertisement

Topics

Alnylam Europe AG Company Profile

10:04 EST 14th December 2018 | BioPortfolio

Alnylam ist ein biopharmazeutisches Unternehmen, das neuartige Therapeutika auf Basis der RNA-Interferenz (RNAi) entwickelt und hierbei eine führende Position inne hat. Die RNAi stellt einen Durchbruch in der Biologie dar. Alnylams Produkt-Pipeline baut auf der RNAi als leistungsfähiger Plattform auf und hat zum Ziel, eine breitgefächerte neue Klasse von Therapeutika zur Behandlung einer Reihe von bedeutenden Erkrankungen hervorzubringen.
Alnylam wurde von führenden Wissenschaftlern gegründet, die zu den Pionieren bei der Entdeckung der RNAi gehören. Das Unternehmen setzt eine Technologie ein, mit der man sehr spezifisch und wirkungsvoll die Expression krankheitsverursachender Gene hemmen kann. Die RNAi ist ein natürlich vorkommender, zellulärer Prozess, durch den Gene spezifisch abgeschaltet werden können. Unter Ausnutzung dieses natürlichen Mechanismus entwickelt Alnylam neuartige Therapeutika, die selektiv solche Gene hemmen, deren Proteine eine schädliche Rolle bei der Krankheitsentstehung spielen.

Alnylam verfügt über hervorragende Voraussetzungen, um das Potenzial der RNAi für therapeutische Anwendungen voll auszuschöpfen. Alnylam ist das weltweit erste Unternehmen, das sich auf RNAi-Therapeutika spezialisiert hat. Es gründet sich auf die führende Expertise ihrer beiden operativen Einheiten, nämlich Alnylam Pharmaceuticals, Cambridge, Massachusetts, USA, gegründet im Jahr 2002, und der Ribopharma AG, Kulmbach, Deutschland, gegründet im Jahr 2000. Letztere firmiert heute unter Alnylam Europe AG und ist ein Tochterunternehmen von Alnylam Pharmaceuticals.

Location

Fritz-Hornschuch-Str. 9
Kulmbach
95326
Germany

Contact

Phone: 49 9221 82762-0
Fax: 49 9221 82762-99


News Articles [246 Associated News Articles listed on BioPortfolio]

RNAi Hits Europe as EMA Follows FDA, Approves Alnylam Drug

The first medicine that uses RNA interference, a method cells employ to mute a gene before it can make a harmful protein, has made its way to Europe. Three weeks after the FDA approved patisiran (Onpa...

Alnylam And Silence Settle Over RNAi Patents

Silence will receive a small royalty on future sales of Alnylam’s Onpattro in Europe, and Alnylam is free to use...   

Alnylam’s RNA therapy Onpattro bags EU nod

Alnylam’s RNAi therapeutic Onpattro has been approved for use in Europe to treat adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis.

Alnylam Won’t Seek Quick FDA Nod For Second RNAi Drug

A few weeks ago, Alnylam Pharmaceuticals indicated it might seek a speedy FDA approval for what could be the second-ever RNA interference medicine to market. After meeting with regulators, however, th...

With New Data, Alnylam Could Seek Speedy OK For Second RNAi Drug

Alnylam Pharmaceuticals was just cleared to market the first-ever RNA interference medicine. The second one may not be that far behind. Alnylam (NASDAQ: ALNY), of Cambridge, MA, said this morning that...

Alnylam Gets Landmark FDA OK For First-Ever RNAi Drug

[Updated at 3:25 pm ET, see below] Alnylam Pharmaceuticals made history this afternoon. The FDA has just approved Alnylam’s patisiran (Onpattro), making it the first medicine specifically cleared to...

Alnylam seeks MHRA approval to start ALN-AAT02 phase 1/2 trial

ALN-AAT02 is Alnylam’s first investigational RNAi therapeutic utilizing the Company’s enhanced stabilization chemistry plus (ESC+) GalNAc-conjugate technology. Alnylam ALN-AAT02 program lead vice ...

Alnylam's Onpattro cleared in Europe as ICER sets pricing battle

Regulators OK'd the first RNA interference therapy in Europe, but a new report finds the list price between 967% and 1,821% above value thresholds.

Drugs and Medications [4 Associated Drugs and Medications listed on BioPortfolio]

Nizatidine [Dispensing Solutions Inc.]

Nizatidine Capsules USP Rx only

Akne-mycin [CORIA LABORATORIES]

Akne-mycin (Erythromycin)

Manicure by opi - finishing butter [OPI Products, Inc]

MANICURE by OPI FINISHING BUTTER

Retavase [EKR Therapeutics, Inc.]

Retavase Reteplase, recombinant

PubMed Articles [343 Associated PubMed Articles listed on BioPortfolio]

Alnylam launches era of RNAi drugs.

Towards the risk of Yellow Fever transmission in Europe.

Yellow fever (YF) is an emerging expanding fatal arboviral disease that has been imported at least six times in Europe during the first half of 2018, while only seven travel-associated YF cases have b...

Infectious disease profiles of Syrian and Eritrean migrants presenting in Europe: A systematic review.

In the past decade, a large influx of migrants presented in Europe. Their country of origin was mainly either Syria or Eritrea. Public health institutions in host countries in Europe are challenged to...

The removal of DAA restrictions in Europe - one step closer to eliminating HCV as a major public health threat.

Of ∼10.2 million people with chronic HCV infection in Europe, most are living in Eastern Europe (6.7 million) followed by Western Europe (2.3 million) and Central Europe (1.2 million). HCV transmiss...

The evolutionary history of human populations in Europe.

I review the evolutionary history of human populations in Europe with an emphasis on what has been learned in recent years through the study of ancient DNA. Human populations in Europe ∼430-39kya (a...

Clinical Trials [622 Associated Clinical Trials listed on BioPortfolio]

In-market Utilisation of Liraglutide Used for Weight Management in Europe: a Retrospective Medical Record Review Study

This study is conducted in Europe. The aim of this study is to investigate usage of liraglutide for weight management in clinical practice.

Description/Characterisation of Asthmatics Eligible for Biologic Therapy Referral in Prim. and Sec. Care in Europe

This is a multi-country, multicentre, observational cross-sectional one-visit study of patients with severe asthma in primary and secondary care settings in Europe

RITE-EUROPE (Radiofrequency-Induced Thermochemotherapy Effect-EUROPE)

This multicenter, prospective, single-arm, phase 3 study will assess the proportion of disease-free patients, starting from administration of the first study treatment to at least 12-month...

EUROpE-RSI (EURopean Online Evaluation RSI Study)

The investigators want to identify and show differences in standards and procedures of in-hospital rapid sequence induction by collecting data with an online survey for anaesthetist in Eur...

A Study Measuring Quality of Life, Treatment Preference and Satisfaction of ADPKD Patients in Europe

This is a prospective, non-interventional study (NIS) measuring health-related quality of life (HRQoL), treatment satisfaction, and other patient-reported outcomes (PROs) of ADPKD patients...

Companies [861 Associated Companies listed on BioPortfolio]

Alnylam Europe AG

Alnylam ist ein biopharmazeutisches Unternehmen, das neuartige Therapeutika auf Basis der RNA-Interferenz (RNAi) entwickelt und hierbei eine führende Position inne hat. Die RNAi stellt einen Durchbru...

Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, a leader in RNAi therapeutics, is a biopharmaceutical company developing novel therapeutics based on a breakthrough in biology known as RNA interference, or RNAi; a discovery ...

Alnylam Pharmaceuticals, Inc.

Alnylam is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. The company is leading the translation of RNAi as a new class of innovative medicines with a ...

Vir Biotechnology, Inc. and Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals, Inc. and The Medicines Company

More Information about "Alnylam Europe AG" on BioPortfolio

We have published hundreds of Alnylam Europe AG news stories on BioPortfolio along with dozens of Alnylam Europe AG Clinical Trials and PubMed Articles about Alnylam Europe AG for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Alnylam Europe AG Companies in our database. You can also find out about relevant Alnylam Europe AG Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Bioinformatics
Bioinformatics is the application of computer software and hardware to the management of biological data to create useful information. Computers are used to gather, store, analyze and integrate biological and genetic information which can then be applied...


Corporate Database Quicklinks



Searches Linking to this Company Record